Nurix Therapeutics (NRIX) Cash from Operations (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash from Operations data on file, last reported at 96573000.0 in Q2 2026.

• On a quarterly basis, Cash from Operations fell 52.9% year-over-year to 96573000.0 in Q2 2026; TTM through May 2026 was 293704000.0, a 36.49% decrease from a year earlier, with the FY2025 full-year figure at 249465000.0, down 44.55% from the prior year.
• Cash from Operations for Q2 2026 stood at 96573000.0, down from 71914000.0 in the prior quarter.
• Over the last five years, Cash from Operations for NRIX reached as high as 26689000.0 in Q4 2023 and fell as low as 96573000.0 in Q2 2026.
• Historically, Cash from Operations has averaged 46206000.0 across 5 years, with a median of 44469000.0 in 2022.
• Across the five-year window, Cash from Operations tumbled 629.37% in 2022 and jumped 170.32% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 37955000.0 in 2022, then soared by 170.32% to 26689000.0 in 2023, then plunged by 282.66% to 48751000.0 in 2024, then sank by 39.14% to 67832000.0 in 2025, then tumbled by 42.37% to 96573000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 96573000.0 in Q2 2026, 71914000.0 in Q1 2026, and 67832000.0 in Q4 2025.